Alloy Therapeutics key facts
as of Oct 2026- Developer of biotechnology platforms intended for drug discovery and development.
- Alloy Therapeutics is valued at approximately $1.0B as of Oct 2026, set at its later-stage round, Apr 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $174.0M across 3 recorded rounds; the latest was Early Stage VC ($30.0M) in Mar 2026.
- Notable investors include Gaingels, Founders Fund, 8VC, Calm Ventures, OurCrowd — 24 tracked in total.
- Alloy Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently Apr 2026 ($30.0M sold to 11 investors).
- Status: Privately Held (backing).
Valued at $1.0B at its later-stage round, Apr 2026. Nothing has traded since.
- ·The complete investor list: 24 names
- ·Watch Alloy Therapeutics: the Monday email on marks, rounds and moves
Alloy Therapeutics funding rounds
3 roundsWho backs Alloy Therapeutics
24+Membership and data by Private Market View
Alloy Therapeutics valuation
Alloy Therapeutics was valued at $1 billion at its later-stage round in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Alloy Therapeutics raised?
Alloy Therapeutics has raised $174 million across 3 recorded rounds since 2021. The largest was a $75 million later-stage round in Mar 2021; the most recent was a $30 million early-stage round in Mar 2026.
Alloy Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently in Apr 2026 ($30 million sold to 11 investors).
Alloy Therapeutics investors
24 investors are on record for Alloy Therapeutics, including Gaingels, Founders Fund, 8VC and Calm Ventures. By type, the record holds 5 venture capital firms and 2 family offices. The early-stage round in Mar 2026 drew 11 investors.
About Alloy Therapeutics
Developer of biotechnology platforms intended for drug discovery and development. The company's platform provides engineered biological systems, data-driven systems, antibody discovery capabilities, and integration with machine learning techniques to support target identification, optimization, and preclinical research workflows, enabling pharmaceutical and biotechnology organizations to improve efficiency and reduce uncertainty in therapeutic development processes.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2017
- Employees
- 137
- Website
- alloytx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.